Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,194 people get ESRX articles and Market Currents by email alert.
Get email alerts on ESRX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (May 8, 2013)
-
Looking Into The Specialty Pharmacy SectorDutch Trader • Wed, May 1
-
PR Newswire (Apr 29, 2013)
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Apr 22, 2013)
-
What's Next For Cardinal Health?Deep Dives • Tue, Mar 19
To learn more about Seeking Alpha Pro, click here.
-
Your Earnings Season Preview: Express ScriptsXY Trader • Mon, Mar 18
-
Approved Express Scripts Merger Paves Way For DistributorsPaul Nouri • Mon, Apr 2, 2012
-
Looking Into The Specialty Pharmacy SectorDutch Trader • Wed, May 1
-
What's Next For Cardinal Health?Deep Dives • Tue, Mar 19
-
Undervalued Top Picks By Brave Warrior FundFAF Research • Thu, Mar 14
-
Express Scripts CEO Discusses Q3 2010 Results - Earnings Call TranscriptThu, Oct 28, 2010
-
Express Scripts Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Express Scripts Q1 2010 Earnings Call TranscriptThu, Apr 29, 2010
-
Express Scripts, Inc. Q4 2009 Earnings Call TranscriptThu, Feb 25, 2010
-
Express Scripts Inc. Q3 2009 Earnings Call TranscriptFri, Oct 30, 2009
-
Express Scripts, Inc. Q2 2009 Earnings Call TranscriptFri, Jul 31, 2009
-
Express Scripts, Inc. Q1 2009 Earnings Call TranscriptFri, May 1, 2009
-
Express Scripts 2008 Earnings Call TranscriptThu, Feb 26, 2009
-
Express Scripts Inc. Q3 2008 Earnings Conference Call TranscriptFri, Oct 31, 2008
-
Express Scripts, Inc. Q2 2008 Earnings CallThu, Jul 31, 2008
-
PR Newswire (May 8, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 29, 2013)
-
PR Newswire (Apr 29, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at MarketWatch.com (Apr 29, 2013)
-
at CNBC.com (Apr 26, 2013)
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Apr 22, 2013)
-
at CNBC.com (Mar 19, 2013)
-
at Fox Business (Mar 19, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 7, 2013)
-
at Fox Business (Mar 5, 2013)
-
at CNBC.com (Mar 5, 2013)
-
at MarketWatch.com (Feb 28, 2013)
-
at MarketWatch.com (Feb 25, 2013)
-
PR Newswire (Feb 20, 2013)
ESRX vs. ETF Alternatives
Company Description
Prescription drugs play a significant role in healthcare today and constitute the first line of treatment for many medical conditions. As pharmaceutical research increases the potential for even more effective drugs, demand can be expected to increase. For millions of people, prescription drugs... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 13, 8:02 AM With Express Scripts (ESRX) now on the verge of regaining its October highs following a strong Q1, Jefferies "hops back on" with a Buy call. "With a good membership baseline now established for 2013 and contracting visibility for 2014 improving, we believe downside risk has moderated meaningfully and the stock should begin to gradually creep up as ESRX demonstrates anew its ability to deliver consistent and predictable operating results and earnings growth." Comment! [Quick Ideas, Healthcare]
- Thursday, May 9, 3:18 PM U.K. mobile banking specialist Monitise PLC (MONIF.PK +9.1%) pops as Lee Cooperman - presenting at SALT in Las Vegas - calls it his top conviction pick: "no financial risk .. no debt ... the blessing of Visa." He owns more than 10% of the company. Other top picks: ESRX, QCOM, C, AIG, MET, and RIG. 3 Comments [Quick Ideas]
- Monday, April 29, 7:31 PM More on Express Scripts (ESRX): Q1 results beat across the board as revenue more than doubled Y/Y. Net earnings rose 39% as the pharmacy-benefit manager's revenue surged, helped by its Medco acquisition. Gross margin widened to 7.5% from 6.9%, including retail pharmacy co-payments. The company raises its full-year earnings outlook by $0.03 a share, now seeing its EPS coming in at $4.23 to $4.33. Shares +2.1% AH. 1 Comment [Earnings, On the Move, Healthcare]
- Monday, April 29, 4:03 PM Express Scripts (ESRX): Q1 EPS of $0.99 beats by $0.02. Revenue of $26.0B beats by $0.46B. Shares +2.3% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Monday, April 29, 12:10 AM Notable earnings after Monday’s close: ANAD, ANH, BWLD, CBL, CRK, CSE, CYH, DTLK, ESRX, GGP, HIG, HLF, HTZ, IDTI, JEC, MAS, MSTR, NEM, PCL, QGEN, RGR, RJET, RVBD, SBAC, SSW, SU, TXRH, VECO 1 Comment [Earnings]
- Sunday, April 28, 5:35 PM Notable earnings after Monday’s close: ANAD, ANH, BWLD, CBL, CRK, CSE, CYH, DTLK, ESRX, GGP, HIG, HLF, HTZ, IDTI, JEC, MAS, MSTR, NEM, PCL, QGEN, RGR, RJET, RVBD, SBAC, SSW, SU, TXRH, VECO 1 Comment [Earnings]
- Tuesday, April 9, 4:53 PM Express Scripts (ESRX) says investors should not accept a "mini-tender" offer from TRC Capital for 2M shares at $55.75 per share. "Mini-tender offers are designed to … avoid many disclosure and procedural requirements of the SEC and … as a result do not provide investors with the same level of protection" as larger tenders, the company says. ESRX notes that the offered price is more than 2% below the current market price. 1 Comment
- Friday, April 5, 6:19 PM J.P. Morgan's Thomas Lee notes that several laggards in the first quarters of 2009-12 rebounded in Q2, so he figures select tech stocks look appealing now. Tech's forward P/E ratio is below the market's for the first time in 17 years, Lee says. His most noteworthy call is to buy Apple (AAPL), which slid 16% Q/Q. Some other favorites: BRCM, CHKP, ESRX, MYL, TASR, CHS, F, COF. 14 Comments [Tech, Quick Ideas]
- Tuesday, February 19, 4:49 AM Express Scripts (ESRX): Q4 EPS of $1.05 in line. Revenues of $27.41B (+126.5% Y/Y) beat by $60M. Net profit +74% to $504.1M, with earnings boosted by the acquisition of Medco and increasing use of generic drugs. Number of claims more than doubles to almost 411M. Forecasts 2013 EPS of $4.20-4.30 vs consensus of $4.21. (PR) Comment! [Earnings, Healthcare]
- Thursday, December 20, 2012, 10:23 AM Vivus (VVUS +4%) moves up this morning after it announced that Express Scripts (ESRX +0.2%) has added its weight-loss drug Qsymia to its national pharmacy formularies. The drug has been added as a standard benefit option in a tier-3 position with a prior authorization. Under the plan, participating patients will now pay around $50 to $60 for their co-payment for a monthly prescription, which equates to approximately one-third of the retail price. 3 Comments [Healthcare, On the Move]
-
Tuesday, November 6, 2012, 9:11 AM
Premarket gainers: JIVE +14%. ROSG +9%. PSTI +8%. ACAD +7%. MIPS +6%. LF +6%. CTRP +5%. VRNG +5%.
Losers: SREV -33%. Z -16%. ESRX -11%. FOSL -10%. VVUS -5%. NVO -5%. Comment! [On the Move] - Tuesday, November 6, 2012, 8:46 AM Express Scripts (ESRX) plunges 12.6% following its Q3 report late yesterday, when it said analysts' 2013 forecasts are "overly aggressive." ESRX said EPS would grow but didn't provide specifics, while the Street expects $4.50/share. A "weak business climate and the unemployment outlook" may lead to a loss of members, depressed drug utilization and "increased client demands and expectations," Express Scripts said. 1 Comment [Earnings, On the Move, Healthcare]
- Monday, November 5, 2012, 4:05 PM Express Scripts (ESRX): Q3 EPS of $1.02 beats by $0.03. Revenue of $27B misses by $400M. Shares -6.7% AH. (PR) Comment! [Earnings, On the Move]
- Monday, November 5, 2012, 12:10 AM Notable earnings after Monday’s close: ALNY, CF, CLNE, CTRP, CVI, DEPO, ED, ENOC, EOG, ESRX, FIS, FNF, JIVE, LF, LYV, MDR, MED, MM, MMLP, MR, MYGN, NRP, PAA, PDLI, PNG, SBAC, TEG, THQI, TWTC, UAN, VVC, WLT, WTW, XL, Z Comment! [Earnings]
- Sunday, November 4, 2012, 5:35 PM Notable earnings after Monday’s close: ALNY, CF, CLNE, CTRP, CVI, DEPO, ED, ENOC, EOG, ESRX, FIS, FNF, JIVE, LF, LYV, MDR, MED, MM, MMLP, MR, MYGN, NRP, PAA, PDLI, PNG, SBAC, TEG, THQI, TWTC, UAN, VVC, WLT, WTW, XL, Z Comment! [Earnings]
- Tuesday, August 28, 2012, 3:24 AM A judge yesterday dismissed most of the claims from pharmacy groups that Express Scripts' (ESRX) $29B acquisition of Medco breaches antitrust law. However, the judge allowed the plaintiffs to replead, and said their claims over clinical specialty drugs can move forward. Comment! [Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.















